GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Recently announced provisional Q4 numbers are positive. Company has provided new information in recent conferences on product testing as the pipeline develops.

GW Pharma Well Placed For Further Progress In 2021 And Beyond

Aurora Cannabis

Aphria

Arena Pharmaceuticals

HEXO Corp

Village Farms International

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis industry will develop in the new year.

Six Marijuana Stocks Stay Hot During a Short Week

Canopy Growth

OrganiGram Holdings Inc.

SNDL Inc.

Molson Coors Brewing

9 Cannabis Stocks Heating Up Headlines This Week

GW Pharmaceuticals plc. (GWPH) CEO Justin Gover on 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)

Green Thumb Industries Inc.

Altria

Trulieve Cannabis Corp.

Curaleaf Holdings, Inc.

Many marijuana stocks show promise in 2021, but these specific stocks have the best shot to build upon their strong performances last year. The post The Top 7 Marijuana Stocks to Buy for January appeared first on InvestorPlace.

The Top 7 Marijuana Stocks to Buy for January

Cronos Group

These cannabis stocks currently have the most green.

5 Marijuana Stocks With the Most Cash in 2021

GW Pharmaceuticals PLC provided an upbeat outlook for fourth-quarter sales, amid strength in sales of Epidiolex, the first cannabis-based drug to be approved by the Food and Drug Administration. The stock fell 2.5% in premarket trading.

GW Pharmaceuticals provides upbeat total and Epidiolex sales outlooks; stock declines

BioNTech SE

Pfizer

Taiwan Semiconductor Manufacturing

Add these top growth stocks to your portfolio before it's too late.

Your 3 Best Profit Opportunities in 2021

GrowGeneration Corp

Innovative Industrial Properties

The rapidly growing cannabis industry now has 10 companies at or above a $2 billion market cap.

The 10 Largest Marijuana Stocks in 2021

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline, please note the time of the conference and breakout session have changed. The conference will be held Tuesday, January 12, 2021 at 10:00 am ET (7:00 am PT). The breakout session will follow at 10:20 am ET (7:20 am PT). Complete corrected release follows:

CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this past week and look ahead to how the cannabis industry will develop in the new year.

Six Cannabis Stocks Getting Busy Ahead of a 'Green Christmas'

EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized

JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex

Analysts believe these pot stocks are budding with opportunity.

5 Marijuana Stocks With Upside of 49% to 83%, According to Wall Street

GW Pharmaceuticals Plc is a pharma company and a global leader in developing cannabinoid-based medicines. Its multiple sclerosis drug nabiximols (brand name Sativex) was the first natural cannabis plant derivative to gain FDA approval.

GW Pharmaceuticals: The One 'Cannabis Stock' Everyone Should Own

AbbVie

Medicinal cannabis is no longer speculative. There are truly impactful treatments out there, as well as investment-worthy marijuana stocks.

7 Medical Marijuana Stocks for a Healthcare Revolution

LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference on Thursday, December 10, 2020 at 11:00am EST.

GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in the upcoming week.

This Week in Cannabis: 6 Stocks Pivoting for Serious Growth

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: GW Pharmaceuticals

- Meeting Highlights Include New Long-Term D ata in Tuberous Sclerosis Comple x -

Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Amplify Alternative Harvest ETF

Cannabis stocks continued their postelection rise from the ashes Monday, ahead of votes this week regarding decriminalization in the U.S. House of Representatives and the United Nations.

Cannabis Watch: Pot stocks pop ahead of U.S., UN votes on cannabis legalization

LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST.

GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

Cambria Cannabis ETF

Getting exposure to the cannabis industry's upside has never been safer or cheaper.

Is Now A Great Time to Buy Pot Stocks?

Getting exposure to the marijuana industry has never been easier.

Here's Why Quants Are Getting Into Cannabis Investing

Greenlane Holdings

New Age Beverages

Therapix Biosciences

9 Pot Stocks That Made Big Moves This Week

GW Pharmaceuticals plc (GWPH) CEO Justin Gover presents at Stifel Virtual Healthcare Conference (Transcript)

News for GW Pharmaceuticals Stock (GWPH)